We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the latest move against authorized generics, Mylan Laboratories has filed a lawsuit against rival Watson Pharmaceuticals and brand firm Procter & Gamble (P&G) over a deal that lets Watson market an authorized version of a P&G drug during Mylan’s 180-day marketing exclusivity period for the product.
Expanding drug manufacturing operations into new or existing building structures requires extensive research to ensure that the prospective facility meets current and future business needs, said a team of industry experts specializing in project management and site design.
In the latest initiative to drive down drug costs, Sen. Byron Dorgan (D-N.D.) last week submitted a Canadian drug reimportation plan to HHS Secretary Tommy Thompson for approval as a two-year pilot project.
The FDA has accused a Middletown, Pa., devicemaker of using misleading statements in promotional materials and purporting unapproved devices as cleared.
Aiming to ward off generic competition by an additional six months, Bristol-Myers Squibb (BMS) yesterday filed data with the FDA from two clinical studies involving the pediatric use of its profitable cancer drug Paraplatin (carboplatin).
Generic firms have lost some prominent patent challenges against brand drugs in recent months -- a development that some generic drug industry observers say is not indicative of a trend, but which others warn could become a problem for the generic industry as it continues to mount early challenges to patents.
Part of the goal of policymakers in discarding the average wholesale price (AWP) reimbursement mechanism when they adopted the recent Medicare Rx legislation was to stop drugmakers from marketing the spread between AWP and acquisition costs, but the new average sales price (ASP) reimbursement mechanism creates a new potential for marketing the spread.
Rep. Henry Waxman (D-Calif.) added his voice Friday to a chorus of complaints that the Bush administration is attempting to protect a slice of the global market for a subset of AIDS drugs produced by brand manufacturers.
Early sales figures for Boston Scientific’s drug-coated Taxus stent indicate the device is well on its way to meeting the company’s goal of capturing 70 percent of the U.S. coronary stent market within 70 days of launch.
Justice Department officials have notified Eli Lilly that they have begun a civil investigation into the way the drugmaker markets and promotes its products, Lilly announced yesterday.